AR024109A1 - Naftalen ureas novedosas como mejoradoras de la captacion de la glucosa - Google Patents
Naftalen ureas novedosas como mejoradoras de la captacion de la glucosaInfo
- Publication number
- AR024109A1 AR024109A1 ARP000102572A ARP000102572A AR024109A1 AR 024109 A1 AR024109 A1 AR 024109A1 AR P000102572 A ARP000102572 A AR P000102572A AR P000102572 A ARP000102572 A AR P000102572A AR 024109 A1 AR024109 A1 AR 024109A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- alkyl
- formula
- cyano
- independently
- Prior art date
Links
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title 1
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 title 1
- 239000008103 glucose Substances 0.000 title 1
- 150000003672 ureas Chemical class 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 7
- 150000001875 compounds Chemical class 0.000 abstract 7
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 150000002431 hydrogen Chemical class 0.000 abstract 3
- 102000003746 Insulin Receptor Human genes 0.000 abstract 2
- 108010001127 Insulin Receptor Proteins 0.000 abstract 2
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 230000004936 stimulating effect Effects 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 230000003178 anti-diabetic effect Effects 0.000 abstract 1
- 239000003472 antidiabetic agent Substances 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000004190 glucose uptake Effects 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 201000001421 hyperglycemia Diseases 0.000 abstract 1
- 230000002452 interceptive effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/45—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
- C07C309/51—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
- C07C311/47—Y being a hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C335/04—Derivatives of thiourea
- C07C335/16—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C335/04—Derivatives of thiourea
- C07C335/16—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C335/18—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C335/30—Isothioureas
- C07C335/32—Isothioureas having sulfur atoms of isothiourea groups bound to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/30—Oxygen or sulfur atoms
- C07D233/32—One oxygen atom
- C07D233/36—One oxygen atom with hydrocarbon radicals, substituted by nitrogen atoms, attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4021—Esters of aromatic acids (P-C aromatic linkage)
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicinal Preparation (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Compuestos de formula (1), en donde R1 y R2 son sustituyentes de los anillos A y son, independientemente, -SO2NR72, -C(O)NR72, -NR7SO2R7, -NR7C(O)R7,-SO2OR7, -C(O)OR7, -OSO2R7, o -OC(O)R7; R3 y R4 son, independientemente, hidrogeno o alquilo inferior, o R3 y R4 conjuntamente son -(CH2)2-, -(CH2)3-, o-(CH2)4-, o R3 o R4 pueden ser un par electronico; R5 y R6 son, independientemente, hidrogeno, alquilo, alquilo sustituido, ciano, halo, nitro, -SR8, -C(O)R8,-SO2OR8, -OSO2R8, -SO2NR82, -NR8SO2R8, -OC(O)R8, -C(O)OR8, -C(O)NR82,NR8C(O)R8, -OR8, o -NR82; cada uno de R7 y R8 es, independientemente, hidrogeno, alquilo,alquilo sustituido, arilo, arilo sustituido, arilalquilo (inferior), arilalquilo (inferior) sustituido, heteroarilalquilo(inferior),heteroarilalquilo(inferior)sustituido, heterociclilo, heterociclilo sustituido, heteroarilo, o heteroarilo sustituido; cada Y es, independientemente, un sustituyente no interferente queno está unido al anillo de naftaleno por medio de un enlace azo oamida; cada x es, independientemente, 0, 1, o 2, y el nexo es un compuesto de formula (2)donde K es O, S, o N-R*, y R* es H, ciano o alquilo inferior; o un compuesto de formula (3) o (4) donde R* es H o alquilo inferior; o un compuesto de formula(5)o (6) donde R* es H, ciano o alquilo inferior; o un compuesto de formula (7) donde R* es ciano o alquilo inferior; y donde, si R1 y R2 son ambos -SO2OH,entonces: (i) ningun grupo Y es -SO2OH; (ii) ni R5 ni R6 son -SO2OR8 u -OSO2R8; y (iii) R5 y R6 nose eligen ambos del grupo integrado por hidroxi e hidrogenoa no ser que al menos un grupo (Y)x sea (Y)x, en donde x es 1 o 2 e Y es un halogeno, o una sal farmacéuticamente aceptable del mismo, como estereoisomerounico o como mezcla de estereoisomeros, son utiles para tratar condiciones asociadas a la hiperglucemia, especialmente la diabetes de tipo II, condinaftilureas. Estos compuestos son utiles en la estimulacion de la actividad de quinasa del receptor insulínico, la activacion del receptorinsulínico, y laestimulacion de la captacion de glucosa. También se describen composiciones farmacéuticas que comprenden los compuestos antidiabéticos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13612899P | 1999-05-26 | 1999-05-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR024109A1 true AR024109A1 (es) | 2002-09-04 |
Family
ID=22471427
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP000102572A AR024109A1 (es) | 1999-05-26 | 2000-05-26 | Naftalen ureas novedosas como mejoradoras de la captacion de la glucosa |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US6458998B1 (es) |
| EP (1) | EP1181271B1 (es) |
| JP (1) | JP2003500381A (es) |
| KR (1) | KR100746870B1 (es) |
| CN (1) | CN1364156A (es) |
| AR (1) | AR024109A1 (es) |
| AT (1) | ATE287394T1 (es) |
| AU (1) | AU776438C (es) |
| BR (1) | BR0011550A (es) |
| CA (1) | CA2374225A1 (es) |
| CZ (1) | CZ20014153A3 (es) |
| DE (1) | DE60017554T2 (es) |
| EA (1) | EA006763B1 (es) |
| ES (1) | ES2233386T3 (es) |
| HK (1) | HK1046399A1 (es) |
| HU (1) | HUP0201306A3 (es) |
| IL (2) | IL146576A0 (es) |
| MX (1) | MXPA01012079A (es) |
| NO (1) | NO20015713L (es) |
| NZ (1) | NZ515743A (es) |
| PL (1) | PL352631A1 (es) |
| TR (1) | TR200103409T2 (es) |
| TW (1) | TWI234557B (es) |
| UA (1) | UA73738C2 (es) |
| WO (1) | WO2000071506A2 (es) |
| ZA (1) | ZA200109641B (es) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7058589B1 (en) * | 1998-12-17 | 2006-06-06 | Iex Corporation | Method and system for employee work scheduling |
| US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| EP1158985B1 (en) | 1999-01-13 | 2011-12-28 | Bayer HealthCare LLC | OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS |
| EP1288199A4 (en) | 2000-04-28 | 2005-10-12 | Shionogi & Co | INHIBITORS OF MMP-12 |
| ITTO20010950A1 (it) * | 2000-10-11 | 2003-04-09 | Telik Inc | Attivatori di recettori di insulina per il trattamento di disturbi metabolici in esseri umani che risultano dal trattamento di infezioni da |
| US6528037B2 (en) | 2000-10-11 | 2003-03-04 | Telik, Inc. | Method for determining whether a compound is an insulin receptor kinase activator |
| PE20021091A1 (es) * | 2001-05-25 | 2003-02-04 | Aventis Pharma Gmbh | Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion |
| JP4636486B2 (ja) | 2002-02-11 | 2011-02-23 | バイエル、ファーマシューテイカルズ、コーポレイション | 脈管形成阻害活性を有するアリール尿素 |
| DE60327543D1 (de) | 2002-10-21 | 2009-06-18 | Janssen Pharmaceutica Nv | Substituierte tetraline und indane und ihre verwendung |
| DK1636585T3 (da) | 2003-05-20 | 2008-05-26 | Bayer Pharmaceuticals Corp | Diarylurinstoffer med kinasehæmmende aktivitet |
| BRPI0412219B8 (pt) | 2003-07-23 | 2021-07-27 | Bayer Healthcare Llc | compostos ômega-carboxi aril difenil uréia fluoro substituídos e composições farmacêuticas compreendendo os referidos compostos |
| IL160420A0 (en) * | 2004-02-16 | 2004-07-25 | Yissum Res Dev Co | Treating or preventing diabetes with cannabidiol |
| NZ563131A (en) | 2005-04-28 | 2010-09-30 | Ajinomoto Kk | Tricyclic lactam compound as a hypoglycemic agent |
| AU2012200933B2 (en) * | 2005-06-22 | 2015-04-30 | Plexxikon, Inc. | Pyrrolo [2, 3-B] pyridine derivatives as protein kinase inhibitors |
| MY153898A (en) * | 2005-06-22 | 2015-04-15 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
| NZ567132A (en) * | 2005-09-09 | 2011-12-22 | Vertex Pharma | Bicyclic derivatives as modulators of voltage gated ion channels |
| WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
| MX2010000617A (es) | 2007-07-17 | 2010-05-17 | Plexxikon Inc | Compuestos y metodos para modulacion de cinasa, e indicaciones de estos. |
| NZ594398A (en) | 2009-04-03 | 2014-03-28 | Plexxikon Inc | Propane-1-sulfonic acid (3-[5-(4-chloro-phenyl)-1h-pyrrol [2, 3-b] pyridine-3-carbonyl]-2,4-difluoro-phenyl} -amide compositions and uses thereof |
| KR20120102669A (ko) | 2009-11-06 | 2012-09-18 | 플렉시콘, 인코퍼레이티드 | 키나제 조정을 위한 화합물 및 방법, 및 이를 위한 적응증 |
| US9624213B2 (en) | 2011-02-07 | 2017-04-18 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| TWI558702B (zh) | 2011-02-21 | 2016-11-21 | 普雷辛肯公司 | 醫藥活性物質的固態形式 |
| US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH488212A (de) * | 1967-09-01 | 1970-03-31 | Ciba Geigy | Photographisches Material |
| US4118232A (en) * | 1971-04-07 | 1978-10-03 | Ciba-Geigy Ag | Photographic material containing sulphonic acid group containing disazo dyestuffs |
| CA985675A (en) * | 1971-04-07 | 1976-03-16 | Ciba-Geigy Ag | Azo dyestuffs, their manufacture and use |
| US4051176A (en) * | 1976-05-10 | 1977-09-27 | American Cyanamid Company | Ureidophenylenebis(carbonylimino)dinaphthalenetrisulfonic acid compounds |
| US4129591A (en) * | 1976-10-27 | 1978-12-12 | American Cyanamid Company | Ureida-phenylenebis(substituted imino)multianionic substituted dinaphthalene sulfonic acids and salts |
| US4102917A (en) * | 1977-06-01 | 1978-07-25 | American Cyanamid Company | Substituted phenyl naphthalenesulfonic acids |
| US4120891A (en) * | 1977-07-01 | 1978-10-17 | American Cyanamid Company | Ureylene naphthalene sulfonic acids |
| US4132730A (en) * | 1977-07-29 | 1979-01-02 | American Cyanamid Company | Ureylene naphthalene sulfonic acids |
| JPS58191772A (ja) * | 1982-05-06 | 1983-11-09 | Canon Inc | 記録液及びこれを用いたインクジェット記録方法 |
| US4591604A (en) * | 1984-03-28 | 1986-05-27 | American Cyanamid Company | Method of inhibiting the complement system by administering multisulfonated naphthalene ureas |
| DE19521589A1 (de) * | 1995-06-14 | 1996-12-19 | Bayer Ag | Polyfunktionelle Azoreaktivfarbstoffe |
| DK0960335T3 (da) * | 1997-01-15 | 2005-06-20 | Telik Inc | Modulatorer af insulinreceptoraktivitet |
| US5830918A (en) * | 1997-01-15 | 1998-11-03 | Terrapin Technologies, Inc. | Nonpeptide insulin receptor agonists |
| US6140368A (en) * | 1997-05-05 | 2000-10-31 | The Regents Of The University Of California | Naphthols useful in antiviral methods |
-
2000
- 2000-05-20 TW TW089109745A patent/TWI234557B/zh not_active IP Right Cessation
- 2000-05-25 EP EP00936360A patent/EP1181271B1/en not_active Expired - Lifetime
- 2000-05-25 BR BR0011550-9A patent/BR0011550A/pt not_active Application Discontinuation
- 2000-05-25 NZ NZ515743A patent/NZ515743A/en unknown
- 2000-05-25 CA CA002374225A patent/CA2374225A1/en not_active Abandoned
- 2000-05-25 DE DE60017554T patent/DE60017554T2/de not_active Expired - Fee Related
- 2000-05-25 US US09/579,279 patent/US6458998B1/en not_active Expired - Fee Related
- 2000-05-25 CN CN00810853A patent/CN1364156A/zh active Pending
- 2000-05-25 MX MXPA01012079A patent/MXPA01012079A/es active IP Right Grant
- 2000-05-25 EA EA200101231A patent/EA006763B1/ru not_active IP Right Cessation
- 2000-05-25 IL IL14657600A patent/IL146576A0/xx active IP Right Grant
- 2000-05-25 TR TR2001/03409T patent/TR200103409T2/xx unknown
- 2000-05-25 ES ES00936360T patent/ES2233386T3/es not_active Expired - Lifetime
- 2000-05-25 KR KR1020017015133A patent/KR100746870B1/ko not_active IP Right Cessation
- 2000-05-25 JP JP2000619763A patent/JP2003500381A/ja not_active Withdrawn
- 2000-05-25 AU AU51684/00A patent/AU776438C/en not_active Ceased
- 2000-05-25 PL PL00352631A patent/PL352631A1/xx not_active IP Right Cessation
- 2000-05-25 UA UA2001129042A patent/UA73738C2/uk unknown
- 2000-05-25 CZ CZ20014153A patent/CZ20014153A3/cs unknown
- 2000-05-25 WO PCT/US2000/014644 patent/WO2000071506A2/en active IP Right Grant
- 2000-05-25 HU HU0201306A patent/HUP0201306A3/hu unknown
- 2000-05-25 AT AT00936360T patent/ATE287394T1/de not_active IP Right Cessation
- 2000-05-26 AR ARP000102572A patent/AR024109A1/es unknown
-
2001
- 2001-11-19 IL IL146576A patent/IL146576A/en not_active IP Right Cessation
- 2001-11-22 ZA ZA200109641A patent/ZA200109641B/en unknown
- 2001-11-23 NO NO20015713A patent/NO20015713L/no not_active Application Discontinuation
-
2002
- 2002-08-26 HK HK02106271A patent/HK1046399A1/xx not_active IP Right Cessation
- 2002-09-06 US US10/237,583 patent/US7071231B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR024109A1 (es) | Naftalen ureas novedosas como mejoradoras de la captacion de la glucosa | |
| AU616185B2 (en) | Oxazolidinones | |
| AR056893A1 (es) | Compuestos heterociclicos fusionados y no fusionados, antagonistas de receptores mineralocorticoides | |
| PE20021005A1 (es) | Quinazolinas como inhibidores de mmp-13 | |
| PE20001467A1 (es) | Derivados de 4-fenilpiridina como antagonistas del receptor de neuroquinina | |
| CO6321130A2 (es) | Piridinas carboxamidas como inhibidores de la 11 beta-hsd1 | |
| AR061644A1 (es) | Derivados de benzofurano | |
| PE20061377A1 (es) | Compuestos heterociclicos fusionados | |
| PE20010645A1 (es) | Compuestos espiro como antagonistas de los receptores del neuropeptido y | |
| PE20020061A1 (es) | Fenil sulfamoil carboxamidas sustituidas | |
| AR034985A1 (es) | Compuesto biciclico; produccion y uso del mismo | |
| AR074435A1 (es) | Derivados de 1,3-benzotiazol, medicamentos que los contienen y uso de los mismos en el tratamiento del cancer. | |
| CO5590957A2 (es) | Amino-1,3,5-triazinas sustituidas en n con radicales biciclicos quirales, procedimiento para su preparacion, composiciones de las mismas y su uso como herbicidas y reguladores del crecimiento de las plantas | |
| PE20030385A1 (es) | Compuestos de urea como antagonistas de receptores y5 del neuropeptido y | |
| CO5040071A1 (es) | Derivados de aminas biciclicas, procesos para su prepara- cion, y composiciones insecticidas que los comprenden | |
| AR057771A1 (es) | Agonistas adrenoreceptores alfa2c | |
| NO20091678L (no) | Modulatorer av glucokortikoidreseptoren, AP-1, og/eller NF-kappaB aktivitet og deres anvendelse | |
| PE20011030A1 (es) | Combinaciones farmaceuticas que comprenden tegaserod y omeprazol | |
| PE20060604A1 (es) | Derivados del tetrahidronaftaleno como agentes antiinflamatorios y procedimiento para su preparacion | |
| AR087494A1 (es) | Derivados de isoxazolina como compuestos insecticidas | |
| PE20081164A1 (es) | Nuevos compuestos 521 | |
| NZ527249A (en) | Purine derivatives as purinergic receptor antagonists | |
| CO6230982A2 (es) | Compuestos triciclicos que contienen actividad antagonista de factor de liberacion de corticotropina y composiciones farmaceuticas que los contienen | |
| PE20060273A1 (es) | Derivados de tetrahidroisoquinolilsulfonamidas como moduladores del receptor h3 | |
| ATE433440T1 (de) | Harnstoff-linker verbindungen und ihre verwendung als ppar regulatoren |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |